[Lemierre's post-tonsillitis sepsis with meningitis and intravascular consumption coagulopathy as complication of infectious mononucleosis with pansinusitis].
METHODS
24 days after the onset of infectious mononucleosis, clinically and serologically confirmed, an otherwise healthy 18-year-old schoolboy developed a fulminant septicaemia with acute meningitis and loss of consciousness, consumptive coagulopathy and acute renal failure.


METHODS
Computed tomography demonstrated pansinusitis. Lumbar puncture produced purulent cerebrospinal fluid with 11,500 cells/microliters, predominantly granulocytes, protein 205 mg/dl, glucose 19 mg/dl, indicating bacterial meningitis. The suspected diagnosis of posttonsillitis septicaemia (Lemierre's syndrome) was confirmed by repeated demonstration of fusiform gram-negative bacteria in anaerobic blood cultures, identified as Fusobacterium necrophorum. Anaerobic CSF culture grew Prevotella bivia of the Bacteroidaceae family.


METHODS
Both the consumptive coagulopathy and the renal failure were successfully treated and the patient's condition stabilized. The sinuses were surgically drained under high doses of piperacillin/sulbactam and chloramphenicol. Despite the sensitivity of the cultured bacteria to the administered antibiotics the septic temperature continued, but disappeared within 4 days of metronidazole having been added. After 5 weeks of antibiotic treatment, three of them in an intensive care unit, the patient was discharged in good general condition.


CONCLUSIONS
This case illustrates that severe septicaemia caused by rare bacteria may follow an attack of infectious mononucleosis which had taken an uncomplicated course.
Busch
N
N
Medizinische Kliniken II und III, Institut für Medizinische Mikrobiologie und Klinik für Radiologische Diagnostik, Klinikum der Technischen Hochschule Aachen.
Mertens
P R
PR
Schönfelder
T
T
Nguyen
H
H
Marschall
H U
HU
Kierdorf
H
H
Haase
G
G
Urhahn
R
R
Sieberth
H G
HG
Matern
S
S
D058186:Acute Kidney Injury / Q000209:etiology*; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000209:etiology*; D002701:Chloramphenicol / Q000627:therapeutic use; D004211:Disseminated Intravascular Coagulation / Q000209:etiology*; D004322:Drainage; D005500:Follow-Up Studies; D005674:Fusobacterium Infections / Q000188:drug therapy / Q000209:etiology*; D005675:Fusobacterium necrophorum; D006801:Humans; D007244:Infectious Mononucleosis / Q000150:complications*; D008297:Male; D008581:Meningitis / Q000188:drug therapy / Q000209:etiology*; D008795:Metronidazole / Q000008:administration & dosage; D010406:Penicillins / Q000627:therapeutic use; D010878:Piperacillin / Q000627:therapeutic use; D012852:Sinusitis / Q000150:complications* / Q000601:surgery; D013407:Sulbactam / Q000627:therapeutic use; D013577:Syndrome; D013997:Time Factors; D014069:Tonsillitis / Q000150:complications*
D000900:Anti-Bacterial Agents; D010406:Penicillins; D008795:Metronidazole; D002701:Chloramphenicol; D013407:Sulbactam; D010878:Piperacillin